Gencaro bucindolol regulatory update

FDA granted Fast Track designation to Arca’s Gencaro bucindolol to prevent atrial fibrillation/atrial flutter in patients with reduced left ventricular ejection fraction (LVEF). The non-selective beta blocker and mild vasodilator is in Phase IIb/III testing for the indication. Enrollment in the Phase IIb portion is expected to complete by year-end 2016. ...